COR
Cencora, Inc.
NYSEUSDEQUITY
Healthcare
DELAYED
Neutral
+9/100
Last price
316.37
▲ 1.44 (0.46%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
314.93
Day high
316.43
Day low
311.83
Volume
817.89K
Market cap
$60.37B
P/E (TTM)
23.49
52W range
244.82 – 377.54
Trailing performance
Returnvs SPY
1W
+2.85%
+0.9%
1M
-4.41%
-5.6%
3M
+2.20%
-2.3%
6M
-1.41%
-19.6%
YTD
-6.33%
-20.6%
1Y
+4.50%
-11.9%
3Y
+75.79%
-6.5%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
10 more panels on COR open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
-5.27K
Net selling
Buy transactions
11
9.28K shares
Sell transactions
4
14.55K shares
Net transactions
+15
Buys less sells
Sell : buy shares
1.6 : 1
Mixed
Insider-held shares
8.21M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Oct 1, 26 | KRIKORIAN LAZARUS Officer |
SELL | 986 | $298.94K | Direct |
| Oct 1, 26 | SANCHEZ ROBERT E Director |
STOCK | 275 | $0 | Direct |
| Sep 16, 26 | GREENBERG LON R Director |
SELL | 1.28K | $411.26K | Direct |
| Sep 1, 26 | KRIKORIAN LAZARUS Officer |
SELL | 985 | $321.08K | Direct |
| Aug 24, 26 | CAMPBELL ELIZABETH S Officer |
SELL | 11.30K | $3.66M | Direct |
| Jul 31, 26 | COOPER ELLEN Director |
STOCK | 97 | $30.20K | Direct |
| Jul 31, 26 | NALLY DENNIS M Director |
STOCK | 113 | $35.18K | Direct |
| Jul 31, 26 | TYLER LAUREN M. Director |
STOCK | 97 | $30.20K | Direct |
| Jun 30, 26 | CAMPBELL ELIZABETH S Officer |
STOCK | 49 | $12.00K | Direct |
| Jun 30, 26 | BATTAGLIA SILVANA Officer |
STOCK | 58 | $14.00K | Direct |
| Jun 22, 26 | TYLER LAUREN M. Director |
BUY | 550 | $148.63K | Direct |
| Jun 18, 26 | DURCAN DERMOT MARK Director |
BUY | 4.00K | $1.10M | Direct |
| May 28, 26 | DURCAN DERMOT MARK Director |
BUY | 4.00K | $1.07M | Direct |
| May 1, 26 | COOPER ELLEN Director |
STOCK | 99 | $30.10K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BATTAGLIA SILVANA |
Officer | 23.62K | Stock Award(Grant) |
CAMPBELL ELIZABETH S |
Officer | 19.45K | Sale |
CLEARY JAMES F. JR. |
Chief Financial Officer | 160.36K | Conversion of Exercise of derivative security |
COLLIS STEVEN HOWARD |
Officer and Director | 305.91K | Sale |
DURCAN DERMOT MARK |
Director | 31.77K | Purchase |
GREENBERG LON R |
Director | 17.13K | Sale |
KRIKORIAN LAZARUS |
Officer | 15.18K | Sale |
MAUCH ROBERT P. |
Chief Executive Officer | 65.39K | Sale |
NALLY DENNIS M |
Director | 13.19K | Stock Award(Grant) |
WALGREENS BOOTS ALLIANCE, INC. |
Beneficial Owner of more than 10% of a Class of Security | — | Sale |
Fundamentals
Market cap$60.37B
Enterprise value$72.21B
Revenue (TTM)$332.77B
Gross profit$13.18B
EBITDA$5.55B
Net income$2.62B
EPS (TTM)$13.47
Free cash flow$2.04B
Total cash$2.82B
Total debt$14.46B
Book value / share$15.99
Shares outstanding190.83M
Float180.25M
Short % of float2.57%
Dividend yield0.76%
Beta (5Y)0.58
Valuation & profitability ratios
Trailing P/E23.49
Forward P/E15.96
PEG ratio0.66
Price / sales—
Price / book19.79
EV / revenue0.22
EV / EBITDA13.02
Gross margin3.96%
Operating margin1.41%
Profit margin0.79%
Return on equity96.87%
Return on assets3.56%
Debt / equity446.52
Current ratio0.94
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $321.33B | $293.96B | $262.17B | $238.59B | +9.3% |
| Operating revenue | $321.33B | $293.96B | $262.17B | $238.59B | +9.3% |
| Cost of revenue | $309.85B | $284.05B | $253.21B | $230.29B | +9.1% |
| Gross profit | $11.48B | $9.91B | $8.96B | $8.30B | +15.8% |
| Selling, general & admin | $6.49B | $5.66B | $5.31B | $4.85B | +14.7% |
| Total operating expense | $7.54B | $6.75B | $6.27B | $5.54B | +11.7% |
| Operating income | $3.93B | $3.16B | $2.69B | $2.75B | +24.6% |
| Net interest income | -$291.55M | -$156.99M | -$228.93M | -$210.67M | -85.7% |
| Pre-tax income | $2.26B | $2.00B | $2.16B | $2.18B | +12.7% |
| Tax provision | $690.52M | $484.70M | $428.26M | $516.52M | +42.5% |
| Net income | $1.55B | $1.51B | $1.75B | $1.70B | +3.0% |
| Net income to common | $1.55B | $1.51B | $1.75B | $1.70B | +3.0% |
| Basic EPS | 8.02 | 7.60 | 8.62 | 8.15 | +5.5% |
| Diluted EPS | 7.96 | 7.53 | 8.53 | 8.04 | +5.7% |
| EBIT | $2.68B | $2.25B | $2.39B | $2.39B | +18.9% |
| EBITDA | $3.75B | $3.37B | $3.37B | $3.10B | +11.1% |
| Basic shares | 193.82M | 198.50M | 202.51M | 208.47M | -2.4% |
| Diluted shares | 195.21M | 200.28M | 204.59M | 211.21M | -2.5% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $4.36B | $3.13B | $2.59B | $3.39B | +39.1% |
| Cash & short-term investments | $4.36B | $3.13B | $2.59B | $3.39B | +39.1% |
| Accounts receivable | $25.23B | $23.87B | $20.91B | $18.45B | +5.7% |
| Inventory | $20.49B | $19.00B | $17.45B | $15.56B | +7.9% |
| Total current assets | $52.24B | $47.72B | $42.80B | $39.59B | +9.5% |
| Property, plant & equipment | $2.54B | $2.18B | $2.14B | $2.14B | +16.4% |
| Goodwill & intangibles | $17.45B | $13.32B | $14.01B | $12.84B | +31.0% |
| Total assets | $76.59B | $67.10B | $62.56B | $56.56B | +14.1% |
| Total current liabilities | $57.82B | $54.28B | $48.83B | $43.48B | +6.5% |
| Current debt | $117.78M | $576.33M | $641.34M | $1.07B | -79.6% |
| Long-term debt | $7.54B | $3.81B | $4.15B | $4.63B | +97.9% |
| Total debt | $7.66B | $4.39B | $4.79B | $5.70B | +74.6% |
| Total liabilities | $74.84B | $66.31B | $61.89B | $56.49B | +12.9% |
| Retained earnings | $6.53B | $5.42B | $4.32B | $2.98B | +20.6% |
| Shareholder equity | $1.51B | $645.94M | $522.00M | -$211.56M | +133.5% |
| Working capital | -$5.58B | -$6.56B | -$6.03B | -$3.89B | +14.9% |
| Net tangible assets | -$15.94B | -$12.67B | -$13.48B | -$13.05B | -25.8% |
| Shares issued | 297.40M | 296.17M | 294.82M | 292.70M | +0.4% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $1.57B | $1.52B | $1.73B | $1.67B | +3.2% |
| Depreciation & amortisation | $1.07B | $1.12B | $980.85M | $709.84M | -4.5% |
| Stock-based compensation | $147.96M | $148.00M | $124.62M | $93.40M | -0.0% |
| Change in working capital | $35.42M | $298.69M | $874.54M | -$139.66M | -88.1% |
| Operating cash flow | $3.88B | $3.48B | $3.91B | $2.70B | +11.2% |
| Capital expenditure | -$667.98M | -$487.17M | -$458.36M | -$496.32M | -37.1% |
| Investing cash flow | -$4.98B | -$618.10M | -$2.60B | -$368.44M | -705.3% |
| Share buybacks | -$435.47M | -$1.49B | -$1.18B | -$483.70M | +70.8% |
| Dividends paid | -$437.08M | -$416.17M | -$398.75M | -$391.69M | -5.0% |
| Financing cash flow | $2.25B | -$2.33B | -$2.22B | -$1.75B | +196.5% |
| Free cash flow | $3.21B | $3.00B | $3.45B | $2.21B | +7.0% |
| End cash position | $4.39B | $3.30B | $2.75B | $3.59B | +33.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $84.75B | $78.36B | $85.93B | $83.73B | $80.66B | +8.2% |
| Operating revenue | $84.75B | $78.36B | $85.93B | $83.73B | $80.66B | +8.2% |
| Cost of revenue | $81.15B | $74.77B | $82.86B | $80.77B | $77.76B | +8.5% |
| Gross profit | $3.61B | $3.59B | $3.07B | $2.95B | $2.91B | +0.5% |
| Selling, general & admin | $2.13B | $1.98B | $1.80B | $1.75B | $1.67B | +7.8% |
| Total operating expense | $2.40B | $2.23B | $2.06B | $2.01B | $1.93B | +7.9% |
| Operating income | $1.21B | $1.36B | $1.02B | $945.94M | $980.24M | -11.5% |
| Net interest income | -$140.71M | -$140.46M | -$72.41M | -$77.83M | -$81.79M | -0.2% |
| Pre-tax income | $996.39M | $2.09B | $708.64M | -$187.04M | $896.28M | -52.3% |
| Tax provision | $219.73M | $459.04M | $142.51M | $146.03M | $206.53M | -52.1% |
| Net income | $763.52M | $1.64B | $559.65M | -$339.70M | $687.40M | -53.5% |
| Net income to common | $763.52M | $1.64B | $559.65M | -$339.70M | $687.40M | -53.5% |
| Basic EPS | 3.95 | 8.44 | 2.88 | -1.75 | 3.55 | -53.2% |
| Diluted EPS | 3.94 | 8.40 | 2.87 | -1.75 | 3.52 | -53.1% |
| EBIT | $1.15B | $2.24B | $802.00M | -$77.69M | $1.01B | -48.7% |
| EBITDA | $1.43B | $2.51B | $1.07B | $186.31M | $1.27B | -43.0% |
| Basic shares | 193.15M | 194.54M | 194.22M | 193.90M | 193.82M | -0.7% |
| Diluted shares | 193.94M | 195.38M | 195.32M | 193.90M | 195.23M | -0.7% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $2.82B | $2.18B | $1.75B | $4.36B | $2.23B | +29.3% |
| Cash & short-term investments | $2.82B | $2.18B | $1.75B | $4.36B | $2.23B | +29.3% |
| Accounts receivable | $25.45B | $24.89B | $25.98B | $25.23B | $24.56B | +2.2% |
| Inventory | $21.03B | $20.01B | $24.08B | $20.49B | $20.14B | +5.1% |
| Total current assets | $55.34B | $53.14B | $54.15B | $52.24B | $48.81B | +4.1% |
| Property, plant & equipment | $2.84B | $2.81B | $2.45B | $2.54B | $2.43B | +1.2% |
| Goodwill & intangibles | $22.45B | $22.51B | $17.41B | $17.45B | $18.26B | -0.3% |
| Total assets | $83.81B | $81.65B | $78.36B | $76.59B | $73.96B | +2.6% |
| Total current liabilities | $59.20B | $56.13B | $59.13B | $57.82B | $53.96B | +5.5% |
| Current debt | $279.15M | $202.66M | $342.28M | $117.78M | $196.79M | +37.7% |
| Long-term debt | $11.44B | $12.18B | $7.58B | $7.54B | $8.04B | -6.1% |
| Total debt | $11.72B | $12.39B | $7.92B | $7.66B | $8.24B | -5.3% |
| Total liabilities | $80.57B | $78.07B | $76.27B | $74.84B | $71.75B | +3.2% |
| Retained earnings | $9.14B | $8.49B | $6.97B | $6.53B | $6.98B | +7.6% |
| Shareholder equity | $3.05B | $3.40B | $1.91B | $1.51B | $1.98B | -10.2% |
| Working capital | -$3.86B | -$2.99B | -$4.98B | -$5.58B | -$5.14B | -29.1% |
| Net tangible assets | -$19.40B | -$19.11B | -$15.50B | -$15.94B | -$16.27B | -1.5% |
| Shares issued | 190.83M | 298.33M | 298.27M | 297.40M | 297.32M | -36.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | $776.67M | $1.63B | $566.13M | -$333.07M | $689.75M | -52.3% |
| Depreciation & amortisation | $277.43M | $262.98M | $264.27M | $264.00M | $258.97M | +5.5% |
| Stock-based compensation | $28.73M | $28.00M | $66.05M | $25.94M | $23.18M | +2.6% |
| Change in working capital | $1.55B | $481.25M | -$3.40B | $2.23B | -$801.50M | +222.5% |
| Operating cash flow | $2.65B | $1.34B | -$2.31B | $3.13B | $109.25M | +98.3% |
| Capital expenditure | -$226.04M | -$165.62M | -$119.38M | -$249.81M | -$183.22M | -36.5% |
| Investing cash flow | -$240.15M | -$4.87B | -$299.31M | -$321.94M | -$234.69M | +95.1% |
| Share buybacks | -$1.00B | $0 | $0 | $0 | $0 | — |
| Dividends paid | -$116.59M | -$117.46M | -$126.52M | -$107.51M | -$107.49M | +0.7% |
| Financing cash flow | -$1.77B | $3.98B | $43.20M | -$683.78M | $215.48M | -144.4% |
| Free cash flow | $2.43B | $1.17B | -$2.42B | $2.88B | -$73.97M | +107.0% |
| End cash position | $2.86B | $2.24B | $1.81B | $4.39B | $2.28B | +28.1% |
Options analytics
Put / call volume
1.63
Put-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
270.00
-14.7% from spot
ATM implied vol
1.6%
Nearest strike to spot
Skew (10% OTM)
0.0%
Calls bid over puts
Call volume
32
Contracts, this expiry
Put volume
52
Contracts, this expiry
Heaviest call OI
270.00
0 contracts
Heaviest put OI
280.00
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 4.35 | 4.48 | +3.0% |
| Mar 2026 | 4.72 | 4.75 | +0.6% |
| Dec 2025 | 4.04 | 4.08 | +1.0% |
| Sep 2025 | 3.79 | 3.84 | +1.4% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 4.57 | 11 | $87.89B | +5.0% |
| Next quarter | 4.60 | 7 | $89.38B | +4.0% |
| Current year | 17.88 | 14 | $337.03B | +4.9% |
| Next year | 19.83 | 9 | $352.94B | +4.7% |
Analyst targets & ownership
Mean target$369.25
High target$430.00
Low target$330.00
Implied upside16.71%
Analyst count12
ConsensusBUY
Strong buy / Buy4 / 7
Hold3
Sell / Strong sell0 / 0
Held by insiders4.30%
Held by institutions99.61%
Institutions holding1.86K
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
309.09
+2.36% from price
SMA 20
313.69
+0.85% from price
SMA 50
317.90
-0.48% from price
SMA 100
301.03
+5.10% from price
SMA 200
317.92
-0.49% from price
EMA 12
311.73
+1.49% from price
EMA 26
314.06
+0.74% from price
EMA 50
313.39
+0.95% from price
RSI (14)
52.1
Neutral
MACD (12,26,9)
-2.33
Hist 0.25
ATR (14)
8.35
2.64% of price
Realised vol 30D
23.5%
Annualised
Bollinger upper
327.51
20, 2σ
Bollinger lower
299.88
20, 2σ
50 / 200 cross
Death
317.90 vs 317.92
Trend bias
Below 200
-0.49%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
-0.14
Less volatile than market
Correlation to SPY
-0.06
Largely independent
Realised vol 30D
23.5%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-32.6%
Peak to trough
Max drawdown 5Y
-32.6%
Peak to trough
ATR 14
8.35
2.64% of price
Beta (reported)
0.58
5Y monthly, from filing
Short interest
Shares short
4.31M
Prior 4.64M
Change vs prior
-7.1%
Shorts covering
% of float
2.57%
Normal
% of shares out
2.26%
Against total outstanding
Days to cover
3.8
Liquid
Float
180.25M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 8, 26 | RBC Capital | MAINTAINED | Sector Perform | Sector Perform |
| Aug 19, 26 | RBC Capital | INITIATED | — | Sector Perform |
| Aug 11, 26 | Wells Fargo | MAINTAINED | Overweight | Overweight |
| Aug 7, 26 | Morgan Stanley | MAINTAINED | Overweight | Overweight |
| Aug 7, 26 | JP Morgan | MAINTAINED | Overweight | Overweight |
| Aug 6, 26 | UBS | MAINTAINED | Buy | Buy |
| Aug 6, 26 | Evercore ISI Group | MAINTAINED | Outperform | Outperform |
| Jun 24, 26 | B of A Securities | MAINTAINED | Neutral | Neutral |
| Jun 10, 26 | Barclays | MAINTAINED | Overweight | Overweight |
| May 11, 26 | Wells Fargo | MAINTAINED | Overweight | Overweight |
| May 7, 26 | UBS | MAINTAINED | Buy | Buy |
| May 7, 26 | Citigroup | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate$2.40 / yr
Forward yield0.76%
5-year avg yield0.92%
Payout ratio17.45%
Ex-dividend dateAug 14, 2026
Next pay dateAug 31, 2026
Last split2:1
Split dateJun 16, 2009
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-09-25
Corporate Changes & Voting Matters
8-K · 2026-08-14
Corporate Changes & Voting Matters
8-K · 2026-08-12
Corporate Changes & Voting Matters
8-K · 2026-08-05
Annual report of employee stock purchase
11-K · 2026-06-18
Corporate Changes & Voting Matters
8-K · 2026-06-15
Corporate Changes & Voting Matters
8-K · 2026-05-29
Corporate Changes & Voting Matters
8-K · 2026-05-06
Headlines
Eli Lilly and vs. Novo Nordisk A/S: Which Healthcare Stock Is a Better Buy in 2026?
Motley Fool · 20h ago
Cencora Insider Sold Shares Worth $298,935, According to a Recent SEC Filing
MT Newswires · 2d ago
Amgen vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026?
Motley Fool · 3d ago
Cencora Announces Date and Time for Fourth Quarter Fiscal 2026 Earnings Release
Business Wire · 5d ago
2 Cash-Producing Stocks with Promising Prospects and 1 We Brush Off
StockStory · 5d ago
AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?
Motley Fool · 5d ago
1 of Wall Street’s Favorite Stocks with Impressive Fundamentals and 2 We Turn Down
StockStory · 9d ago
AbbVie vs. Pfizer: Which Healthcare Stock Makes Your Portfolio Healthier in 2026?
Motley Fool · 12d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.